A Clinical Study Evaluating the Safety, Tolerability, Pharmacokinetic and Pharmacodynamic Characteristics and Efficacy of Subcutaneous Injection of MSC303 for the Treatment of Immune Glomerular Diseases
Latest Information Update: 17 Jun 2025
At a glance
- Drugs MBS 303 (Primary)
- Indications Glomerulonephritis; Lupus nephritis
- Focus Adverse reactions; Therapeutic Use
Most Recent Events
- 09 Jun 2025 New trial record